Related references
Note: Only part of the references are listed.INTEGRATE: gene fusion discovery using whole genome and transcriptome data
Jin Zhang et al.
GENOME RESEARCH (2016)
Genome Modeling System: A Knowledge Management Platform for Genomics
Malachi Griffith et al.
PLOS COMPUTATIONAL BIOLOGY (2015)
Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor
Dejan Juric et al.
NATURE (2015)
Mechanisms of aromatase inhibitor resistance
Cynthia X. Ma et al.
NATURE REVIEWS CANCER (2015)
Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing
Jianjun Zhang et al.
SCIENCE (2014)
Spatial and temporal diversity in genomic instability processes defines lung cancer evolution
Elza C. de Bruin et al.
SCIENCE (2014)
SciClone: Inferring Clonal Architecture and Tracking the Spatial and Temporal Patterns of Tumor Evolution
Christopher A. Miller et al.
PLOS COMPUTATIONAL BIOLOGY (2014)
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
Weiyi Toy et al.
NATURE GENETICS (2013)
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
Dan R. Robinson et al.
NATURE GENETICS (2013)
Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer
Ron Bose et al.
CANCER DISCOVERY (2013)
Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts
Shunqiang Li et al.
CELL REPORTS (2013)
When to order a biopsy to characterise a metastatic relapse in breast cancer
T. Foukakis et al.
ANNALS OF ONCOLOGY (2012)
The Origin and Evolution of Mutations in Acute Myeloid Leukemia
John S. Welch et al.
CELL (2012)
The Life History of 21 Breast Cancers
Serena Nik-Zainal et al.
CELL (2012)
Pretreatment Epidermal Growth Factor Receptor (EGFR) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non-Small-Cell Lung Cancer
Kang-Yi Su et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Collision Tumors With Synchronous Presentation of Breast Carcinoma and Lymphoproliferative Disorders in the Axillary Nodes of Patients With Newly Diagnosed Breast Cancer: A Case Series
Dietlind L. Wahner-Roedler et al.
CLINICAL BREAST CANCER (2011)
Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor-Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype-ACOSOG Z1031
Matthew J. Ellis et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer
Matthew J. Ellis et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine
M. Gerlinger et al.
BRITISH JOURNAL OF CANCER (2010)
Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC
Alexa B. Turke et al.
CANCER CELL (2010)
Improved Surgical Outcomes for Breast Cancer Patients Receiving Neoadjuvant Aromatase Inhibitor Therapy: Results from a Multicenter Phase II Trial
John A. Olson et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2009)
Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome
Elaine R. Mardis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Predicting response and resistance to endocrine therapy: Profiling patients on aromatase inhibitors
William R. Miller et al.
CANCER (2008)
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics
Matthew J. Ellis et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole
William R. Miller et al.
PHARMACOGENETICS AND GENOMICS (2007)
Incidence and prognosis of synchronous and Metachronous bilateral breast cancer
Mikael Hartman et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Molecular response to aromatase inhibitor treatment in primary breast cancer
Alan Mackay et al.
BREAST CANCER RESEARCH (2007)
Breast cancer-amplified sequence 3, a target of metastasis-associated protein 1, contributes to tamoxifen resistance in premenopausal patients with breast cancer
Anupama E. Gururaj et al.
CELL CYCLE (2006)
Share Paper
